Vilket är priset för TransThera Sciences (Nanjing). Inc. (2617)

Priset för TransThera Sciences (Nanjing). Inc. (2617) är $1.30

Vilket är marknadsvärdet för TransThera Sciences (Nanjing). Inc. (2617)

Marknadsvärdet för TransThera Sciences (Nanjing). Inc. (2617) är $516.38M

TransThera Sciences (Nanjing). Inc. (2617) Vinst

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.

År	Vinst	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Vinst

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Företag

Vinst

Skillnad i vinst

Land